Please try another search
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Bruno Lucidi | 63 | 2014 | Independent Director |
Jean-Pierre Sommadossi | 67 | 2012 | Founder, Chairman, CEO & President |
Franklin M. Berger | 74 | 2019 | Lead Independent Director |
Bruce Polsky | 69 | 2014 | Independent Director |
Barbara G. Duncan | 58 | 2020 | Independent Director |
Jerome M. Adams | 48 | 2021 | Independent Director |
Polly A. Murphy | 59 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review